Clinical outcomes of microscopic residual disease after bronchial sleeve resection for non–small cell lung cancer

Tae Hee Hong, Jhingook Kim, Sumin Shin, Hong Kwan Kim, Yong Soo Choi, Jae Il Zo, Young Mog Shim, Jong Ho Cho

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Objectives: To evaluate the significance of microscopic residual disease (MRD) at the bronchial resection margin after bronchial sleeve resection in non–small cell lung cancer. Methods: We retrospectively reviewed 536 consecutive patients who underwent bronchial sleeve resection between 1995 and 2015. Clinical outcomes, including recurrence and long-term survival, were analyzed according to the bronchial resection margin status (R0 = complete resection and R1 = microscopic residual tumor). Results: Forty patients (7.5%) were identified to have MRD. During a 52.4-month follow-up (range, 0.1-261.0 months), there was no significant difference in 5-year overall survival (61.8% vs 61.5%; P = .550) and 5-year recurrence-free survival (53.7% vs 59.0%; P = .390) between groups R1 and R0. Multivariable cox regression analysis demonstrated that the margin status (group R1) was not associated with significantly decreased overall survival and recurrence-free survival. In group R1, 3 patients (7.5%) showed locoregional recurrence, including 1 patient (2.5%) with anastomotic recurrence. There were no significant differences between both groups in anastomotic recurrence (2.5% vs 2.6%; P = 1.000), locoregional recurrence (7.5% vs 12.7%; P = .476), and distant recurrence (25.0% vs 23.2%; P = .947) rates. Subgroup analysis of group R1 revealed a significant trend toward an increasing recurrence rate as the pathological extent of MRD advanced toward invasive extramucosal carcinoma (P for trend = .015). Conclusions: In our experience of bronchial sleeve resection, the oncologic outcome of MRD was not jeopardized. Furthermore, the pathological extent of MRD might be helpful for recurrence prediction and treatment planning.

Original languageEnglish
Pages (from-to)267-277.e9
JournalJournal of Thoracic and Cardiovascular Surgery
Issue number1
StatePublished - Jan 2021

Bibliographical note

Publisher Copyright:
© 2020 The American Association for Thoracic Surgery


  • lung cancer
  • microscopic residual disease
  • sleeve lobectomy
  • survival


Dive into the research topics of 'Clinical outcomes of microscopic residual disease after bronchial sleeve resection for non–small cell lung cancer'. Together they form a unique fingerprint.

Cite this